Mortality associated with medical therapy versus elective colectomy in ulcerative colitis a cohort study

Annals of Internal Medicine

Volumn 163, Issue 4, 2015, Pages 262-270

  Bewtra, Meenakshi ^a   Newcomb, Craig W ^a   Wu, Qufei ^a   Chen, Lang ^b   Xie, Fenglong ^b   Roy, Jason A ^a   Aarons, Cary B ^c   Osterman, Mark T ^d   Forde, Kimberly A ^a   Curtis, Jeffrey R ^b   Lewis, James D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b University of Alabama at Birmingham   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; ELECTIVE SURGERY; GROUPS BY AGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MEDICAID; MEDICARE; MIDDLE AGED; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL RATE; TOTAL COLON RESECTION; TREATMENT OUTCOME; ULCERATIVE COLITIS; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; AGE; COLITIS, ULCERATIVE; COLON RESECTION; EPIDEMIOLOGY; FEMALE; MALE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL; UNITED STATES;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COLECTOMY; COLITIS, ULCERATIVE; ELECTIVE SURGICAL PROCEDURES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEDICAID; MEDICARE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 84939549265     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-0960     Document Type: Article

References (42)

1. Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am. 2004;33:303-17, ix-x. [PMID: 15177540]
2. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-30. [PMID: 16678077]
3. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134:929-36. [PMID: 18294633] doi:10.1053/j.gastro.2008.01.012
4. Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1428-35. [PMID: 18494836] doi:10.1111/j.1572-0241.2008.01836.x
5. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-76. [PMID: 16339095]
6. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19-31. [PMID: 14699483]
7. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-95. [PMID: 20393175] doi:10.1056/NEJMoa0904492
8. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85. [PMID: 16705109]
9. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-81. [PMID: 19558997] doi:10.1016/j.cgh.2009.01.004
10. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54:1121-5. [PMID: 16009685]
11. Beigel F, Jurgens M, Tillack C, Subklewe M, Mayr D, Goke B, et al. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nat Rev Gastroenterol Hepatol. 2009;6:433-6. [PMID: 19575026] doi:10.1038/nrgastro.2009.87
12. Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update [Letter]. J Pediatr Gastroenterol Nutr. 2009;48:386-8. [PMID: 19274799]
13. Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk. 2010;10: 144-8. [PMID: 20371449] doi:10.3816/CLML.2010.n.021
14. Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;132:516-26. [PMID: 17258720]
15. Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;9:CD000478. [PMID: 22972046] doi:10.1002/14651858.CD000478.pub3
16. Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134:680-7. [PMID: 18242604] doi:10.1053/j.gastro.2008 .01.004
17. Alves A, Panis Y, Bouhnik Y, Maylin V, Lavergne-Slove A, Valleur P. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg. 2003;197:379-85. [PMID: 12946792]
18. Pal S, Sahni P, Pande GK, Acharya SK, Chattopadhyay TK. Outcome following emergency surgery for refractory severe ulcerative colitis in a tertiary care centre in India. BMC Gastroenterol. 2005;5: 39. [PMID: 16316474]
19. Roberts SE, Williams JG, Yeates D, Goldacre MJ. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ. 2007; 335:1033. [PMID: 17977817]
20. Sagar PM, Pemberton JH. Intraoperative, postoperative and reoperative problems with ileoanal pouches. Br J Surg. 2012;99:454-68. [PMID: 22307828] doi:10.1002/bjs.8697
21. Michelassi F, Lee J, Rubin M, Fichera A, Kasza K, Karrison T, et al. Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg. 2003;238:433-41. [PMID: 14501509]
22. Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, Milsom JW, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120-7. [PMID: 7639579]
23. Bach SP, Mortensen NJ. Ileal pouch surgery for ulcerative colitis. World J Gastroenterol. 2007;13:3288-300. [PMID: 17659667]
24. Nicholls RJ, Clark DN, Kelso L, Crowe AM, Knight AD, Hodgkins P, et al. Nationwide linkage analysis in Scotland implicates age as the critical overall determinant of mortality in ulcerative colitis. Aliment Pharmacol Ther. 2010;31:1310-21. [PMID: 20236256] doi:10.1111/j .1365-2036.2010.04302.x
25. Bewtra M, Kilambi V, Fairchild AO, Siegel CA, Lewis JD, Johnson FR. Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis. 2014;20:103-14. [PMID: 24280881] doi:10.1097/01.MIB.0000437498.14804.50
26. Arora G, Singh G, Vadhavkar S, Shah SB, Mannalithara A, Mithal A, et al. Incidence and risk of intestinal and extra-intestinal complications in Medicaid patients with inflammatory bowel disease: a 5-year population-based study. Dig Dis Sci. 2010;55:1689-95. [PMID: 20428948] doi:10.1007/s10620-010-1236-z
27. Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger C, et al. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol. 2014;12: 811-817.e3. [PMID: 23811254] doi:10.1016/j.cgh.2013.06.010
28. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887-95. [PMID: 23462785] doi:10.1001/jama.2013.1099
29. Gross R, Bilker WB, Strom BL, Hennessy S. Validity and comparison of two measures of days supply in Medicaid claims data. Pharmacoepidemiol Drug Saf. 2008;17:1029-32. [PMID: 18442181] doi: 10.1002/pds.1606
30. Hennessy S, Leonard CE, Palumbo CM, Newcomb C, Bilker WB. Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care. 2007;45: 1216-20. [PMID: 18007173]
31. Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2007;5:597-601. [PMID: 17382602]
32. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64:749-59. [PMID: 21208778] doi:10.1016/j.jclinepi.2010.10.004
33. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology. 2003;14:680-6. [PMID: 14569183]
34. Scott FI, Vajravelu RK, Bewtra M, Mamtani R, Lee D, Goldberg DS, et al. The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a Markov model. Clin Gastroenterol Hepatol. 2015;13:302-309.e11. [PMID: 25117775] doi:10.1016/j.cgh .2014.07.058
35. Lichtenstein GR, Cohen R, Feagan BG, Sandborn WJ, Salzberg B, Chen D, et al. Safety of infliximab and other Crohn's disease therapies-TREAT registry data with nearly 24,575 patient years of follow up. Am J Gastroenterol. 2008;103:P14.
36. Bewtra M, Siegel CA, Lewis JD. Ulcerative colitis patients taking immunosuppressive medications report inadequate understanding of surgical options. Gastroenterology. 2012;142(Suppl 1):S794.
37. Waljee AK, Higgins PD, Waljee JF, Tujios SR, Saxena A, Brown LK, et al. Perceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol. 2011;106:794-9. [PMID: 21364547] doi:10.1038/ajg .2011.39
38. McLeod RS, Baxter NN. Quality of life of patients with inflammatory bowel disease after surgery. World J Surg. 1998;22:375-81. [PMID: 9523520]
39. Davies RJ, O'Connor BI, Victor C, MacRae HM, Cohen Z, McLeod RS. A prospective evaluation of sexual function and quality of life after ileal pouch-anal anastomosis. Dis Colon Rectum. 2008;51: 1032-5. [PMID: 18454295] doi:10.1007/s10350-008-9248-x
40. Wexelman BA, Eden E, Rose KM. Survey of New York City resident physicians on cause-of-death reporting, 2010. Prev Chronic Dis. 2013;10:E76. [PMID: 23660118] doi:10.5888/pcd10.120288
41. Ravakhah K. Death certificates are not reliable: revivification of the autopsy. South Med J. 2006;99:728-33. [PMID: 16866055]
42. Ananthakrishnan AN. Environmental triggers for inflammatory bowel disease. Curr Gastroenterol Rep. 2013;15:302. [PMID: 23250702] doi:10.1007/s11894-012-0302-4